Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin versus insulin degludec on branched-chain amino acid metabolism in diabetic nephropathy
ChiCTR2400079844Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin and insulin degludec in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Urinary branched-chain amino acid content. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
henagliflozininsulin degludec
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400079844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079844.